汎血管疾患全過程管理モデル構築探析

  • role: First author第一作者
  • Affiliation:

    Hubei University of Chinese Medicine,Wuhan 430065,China

  • Email:lsy201630030@163.com
  • Introduction:刘淑媛,在读博士,从事中西医结合防治心血管疾病临床与基础研究,E-mail:lsy201630030@163.com
LIU Shuyuan1,  
  • role: Corresponding author通信作者
  • Affiliation:

    Hubei University of Chinese Medicine,Wuhan 430065,China

    Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China

  • Email:wangjie0103@126.com
  • Introduction:王阶,主任医师,博士生导师,从事中西医结合防治心血管病研究,E-mail:wangjie0103@126.com
WANG Jie12*,  
  • Affiliation:

    Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China

LI Jun2,  
  • Affiliation:

    Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China

XIONG Xingjiang2

サマリー

汎血管疾患は、動脈硬化を病理の核心とし、全身の複数の血管床および標的臓器に及ぶ全身性疾患である。その広範性と複雑性の特性により、従来の単一学科防治モデルは系統的な管理ニーズを満たしにくく、臨床診断は偏りや不足が生じやすく、病状の遅延を招く。資料を整理した結果、当該チームは汎血管疾患が広範な病変部位、多数の影響因子を含み、生命と健康に危害を及ぼしやすいため、血管の健康を目標に患者を中心とした総合的な全過程防治管理体制の構築が急務であると考えている。第一に、高リスク群に対する早期スクリーニングおよびリスク評価を実施し、患者の治療方針には多学科協働を要し、科学的で標準化された予防診療パスを確立する。第二に、人を中心に据え、認知介入によって患者の疾病への馴染みやすさを高め、受動的治療から能動的健康へ転換することを重視する。第三に、現代科学技術の利点を十分に活用し、人工知能技術のイノベーションと現代医学との深い融合を推進し、伝統的な診療計画を精密化・知能化・個別化へとアップグレードし、汎血管疾患の全過程管理の現代化の新たな道を開く。第四に、伝統中医学の特色を継承・革新発展させ、現代医薬と伝統医薬の両立を堅持し、中西医の強みを補完し合い、調和的に発展させ、独自の汎血管疾患全過程管理中国モデルを形成する。第五に、政府・医療保険・医療資源の再統合・再配分を通じて汎血管学科の総合的人材を育成し、効率的な階層管理モデルを構築し、将来の複雑性疾患の全過程管理に参考となる意義を提供する。

キーワード

汎血管疾患;全過程管理;中医学管理;人工知能(AI)管理;多学科協働

References

  1. 1.
    Chinese College of Cardiovascular Physicians.Chinese expert consensus on antithrombotic therapy of panvascular diseases (2024 edition)[J].Nat Med J China,2024,104(12):906-923.
  2. 2.
    YANG J,ZHANG Y M,GE J B .Panvascular disease prevention and control:From disease treatment to comprehensive management[J].Chin Video J Cardiol,2021,4(1):1-6.
  3. 3.
    YANG J,WANG K Q,HUO Y,et al.Scientific statement for the prevention and treatment of panvascular disease[J].Chin Circ J,2019,34(11):1041-1046.
  4. 4.
    XU S W,GE J B,WENG J P.Endothelial dysfunction and panvascular diseases[J].J Univ Sci Technol China,2021,51(8):577-585.
  5. 5.
    XU S W,ILYAS I,LITTLE P J,et al.Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond:From mechanism to pharmacotherapies[J].Pharmacol Rev,2021,73(3):924-967.
  6. 6.
    GAO H J,REN J Y,WANG R L,et al.Research progress on the role of endothelial cell injury and dysfunction in atherosclerosis[J].Chin Gen Pract,2025,28(21):2697-2704.
  7. 7.
    PAN Y S,JING J,CAI X L,et al.Prevalence and vascular distribution of multiterritorial atherosclerosis among community-dwelling adults in Southeast China[J].JAMA Netw Open,2022,5(6):e2218307.
  8. 8.
    GARLAND-BAIRD L,FRASER K.Conceptualization of the chronic care model:Implications for home care case manager practice[J].Home Healthc Now,2018,36(6):379-385.
  9. 9.
    VAINAUSKIENĖ V,VAITKIENĖ R.Enablers of patient knowledge empowerment for self-management of chronic disease:An integrative review[J].Int J Environ Res Public Health,2021,18(5):2247.
  10. 10.
    NUÑO R,COLEMAN K,BENGOA R,et al.Integrated care for chronic conditions:The contribution of the ICCC Framework[J].Health Policy,2012,105(1):55-64.
  11. 11.
    LI J,ZHANG H Y,YANG J.Implications of domestic and foreign typical chronic disease management models for rural chronic disease management in China[J].Chin Gen Pract,2022,25(16):1935-1941.
  12. 12.
    ZHU X,CHEN A Y.Enlightenment of foreign classical chronic disease management modes on the management of chronic diseases in China[J].Chin Gen Pract,2023,26(1):21-26.
  13. 13.
    YANG J,ZHANG Y M,GE J B.Screening and early detection of panvascular disease[J].Shanghai Med J,2022,45(5):293-297.
  14. 14.
    PHAM M H X,CHRISTENSEN D M,KRISTENSEN A T,et al.Association of overweight and obesity with coronary risk factors and the presence of multivessel disease in patients with obstructive coronary artery disease-a nationwide registry study[J].Int J Cardiol Cardiovasc Risk Prev,2024,22:200299.
  15. 15.
    GRANDHI G R,MIRBOLOUK M,DARDARI Z A,et al.Interplay of coronary artery calcium and risk factors for predicting CVD/CHD mortality:The CAC Consortium[J].JACC Cardiovasc Imaging,2020,13(5):1175-1186.
  16. 16.
    MITCHELL J D,FERGESTROM N,GAGE B F,et al.Impact of statins on cardiovascular outcomes following coronary artery calcium scoring[J].J Am Coll Cardiol,2018,72(25):3233-3242.
  17. 17.
    BAO X Y,FENG J,LAN M J,et al.A review of the scope of research on clinical biomarkers of pan-vascular diseases[J].Electrocardiol Circ,2023,42(6):596-600,604.
  18. 18.
    MAO Y Q,KANG D D,ZHANG B W,et al.Research progress of multidisciplinary team diagnosis and treatment model in China and abroad[J].Chin Hosp,2022,26(3):18-21.
  19. 19.
    PENG T T,JIANG Y,JIANG X Y,et al.Research on operation process and influencing factors of multi-disciplinary treatment based on group decision-making theory[J].Med Soc,2021,34(12):75-79.
  20. 20.
    YU J,DAI X X,HU L.Practice and experience of one-station service model of disease-based MDT[J].Chin Hosp Manage,2019,39(1):33-34.
  21. 21.
    BI Q.Multidisciplinary integrated management of panvascular diseases[J].Chin J Cerebrovasc Dis,2022,19(3):145-147.
  22. 22.
    WEI S L,ZHOU Y W,XU S W,et al.Risk factors of pan-vascular diseases and their interactions[J].Biomed Transform,2024,5(4):113-124.
  23. 23.
    SUZUKI Y,OZAWA T,KURATA T,et al.A molecular complex of Ca(v)1.2/CaMKK2/CaMK1a in caveolae is responsible for vascular remodeling via excitation-transcription coupling[J].Proc Natl Acad Sci U S A,2022,119(16):e2117435119.
  24. 24.
    EDGAR L,AKBAR N,BRAITHWAITE A T,et al.Hyperglycemia induces trained immunity in macrophages and their precursors and promotes atherosclerosis[J].Circulation,2021,144(12):961-982.
  25. 25.
    BRANDTS J,RAY K K.Novel and future lipid-modulating therapies for the prevention of cardiovascular disease[J].Nat Rev Cardiol,2023,20(9):600-616.
  26. 26.
    YU W,LIU W D,XIE D,et al.High level of uric acid promotes atherosclerosis by targeting NRF2-mediated autophagy dysfunction and ferroptosis[J].Oxid Med Cell Longev,2022,2022:9304383.
  27. 27.
    CALIRI A W,TOMMASI S,BESARATINIA A.Relationships among smoking,oxidative stress,inflammation,macromolecular damage,and cancer[J].Mutat Res Rev Mutat Res,2021,787:108365.
  28. 28.
    RAMAN P,KHANAL S.Leptin in atherosclerosis:Focus on macrophages,endothelial and smooth muscle cells[J].Int J Mol Sci,2021,22(11):5446.
  29. 29.
    LANE M M,GAMAGE E,DU S T,et al.Ultra-processed food exposure and adverse health outcomes:Umbrella review of epidemiological Meta-analyses[J].Bmj,2024,384:e077310.
  30. 30.
    WU C L,GUO J X,YANG J L,et al.Effects of high-fat diet on rat aortic endothelial cell morphology and stiffness[J].Med Biomech,2020,35(4):449-454.
  31. 31.
    WEN J,SUN H,YANG B W,et al.Long-term polystyrene nanoplastic exposure disrupt hepatic lipid metabolism and cause atherosclerosis in ApoE-/- mice[J].J Hazard Mater,2024,466:133583.
  32. 32.
    DE BONT J,JAGANATHAN S,DAHLQUIST M,et al.Ambient air pollution and cardiovascular diseases:An umbrella review of systematic reviews and Meta-analyses[J].J Intern Med,2022,291(6):779-800.
  33. 33.
    WU Z N,CHEN T W,QIAN Y X,et al.High-dose ionizing radiation accelerates atherosclerotic plaque progression by regulating P38/NCOA4-mediated ferritinophagy/ferroptosis of endothelial cells[J].Int J Radiat Oncol Biol Phys,2023,117(1):223-236.
  34. 34.
    ZHANG X,ZHANG F,LI M L,et al.Application and challenges of intelligent robots in grassroots chronic disease management[J].Chin Gen Pract,2025,28(1):7-12,19.
  35. 35.
    XIAO J,LI M Y,CAI R W,et al.Smart pharmaceutical monitoring system with personalized medication schedules and self-management programs for patients with diabetes:Development and evaluation study[J].J Med Internet Res,2025,27:e56737.
  36. 36.
    PROCHASKA J O,DICLEMENTE C C.Transtheoretical therapy:Toward a more integrative model of change[J].Psychother Theory Res Pract,1982,19(3):276-288.
  37. 37.
    JIN G H,XU S M,ZHANG R,et al.A view of the construction of doctor-respected ethics from the cause analysis of conflicts between doctor and patient[J].Chin Med Ethics,2018,31(5):591-596.
  38. 38.
    LOMBARD J H.Depression,psychological stress,vascular dysfunction,and cardiovascular disease:Thinking outside the barrel [J].J Appl Physiol,2010,108(5):1025-1026.
  39. 39.
    ZHU Y Q,HADDAD Y,YUN H J,et al.Induced inflammatory and oxidative markers in cerebral microvasculature by mentally depressive stress [J].Mediators Inflamm,2023,2023:4206316.
  40. 40.
    KATON W,LIN E H B,KROENKE K.The association of depression and anxiety with medical symptom burden in patients with chronic medical illness [J].Gen Hosp Psychiatry,2007,29(2):147-155.
  41. 41.
    YUAN J,LIU Y,LIAO J W,et al.Clinical heterogeneity of post-stroke depression and post-coronary heart disease depression[J].Chin J Gerontol,2020,40(8):1765-1769.
  42. 42.
    MAISTO M,DIANA B,DI TELLA S,et al.Digital interventions for psychological comorbidities in chronic diseases-a systematic review[J].J Pers Med,2021,11(1):30.
  43. 43.
    HASKINS R,GARFINKEL I,MCLANAHAN S.Introduction:Two-generation mechanisms of child development[J].Future Child,2014,24(1):3-12.
  44. 44.
    LI H M,WU Y B,SUN J,et al.Family health and chronic disease control:The mediating role of health literacy,health behavior and trust in primary care services[J].Popul Dev,2023,29(5):145-160.
  45. 45.
    YAN J Q,MENG F L,CHEN Y S,et al.The relationship between perceived social support and medication adherence in patients[J].J Commun Med,2016,14(23):1-4.
  46. 46.
    GONG W Q,GUO Q,JIANG L.The effects of family communication patterns on middle-aged and elderly's coping behavior with epidemic diseases[J].J Zhejiang Univ:Human Soc Sci,2021,51(2):42-53.
  47. 47.
    WANG J Y,KONG X Q,WANG L,et al.Relationships among social support,self-efficacy,and frailty in disabled older adults and their family caregivers:The actor-partner interdependence analysis[J].Chin Nurs Manage,2024,24(12):1836-1841.
  48. 48.
    ZHANG Y,MEI D,XING F M,et al.The correlation between social support,coping styles and resilience among elderly people in the community[J].Chin J Gerontol,2024,44(7):1755-1758.
  49. 49.
    DELPINO F M,COSTA Â K,FARIAS S R,et al.Machine learning for predicting chronic diseases:A systematic review[J].Public Health,2022,205:14-25.
  50. 50.
    AFZAL N,SOHN S,ABRAM S,et al.Mining peripheral arterial disease cases from narrative clinical notes using natural language processing[J].J Vasc Surg,2017,65(6):1753-1761.
  51. 51.
    ROSS E G,SHAH N H,DALMAN R L,et al.The use of machine learning for the identification of peripheral artery disease and future mortality risk[J].J Vasc Surg,2016,64(5):1515-1522.
  52. 52.
    LIU Q,ZHANG M,HE Y F,et al.Predicting the risk of incident type 2 diabetes mellitus in Chinese elderly using machine learning techniques[J].J Pers Med,2022,12(6):905.
  53. 53.
    LI Q,CAMPAN A,REN A,et al.Automating and improving cardiovascular disease prediction using machine learning and EMR data features from a regional healthcare system[J].Int J Med Inf,2022,163:104786.
  54. 54.
    JOHRI A M,SINGH K V,MANTELLA L E,et al.Deep learning artificial intelligence framework for multiclass coronary artery disease prediction using combination of conventional risk factors,carotid ultrasound,and intraplaque neovascularization[J].Comput Biol Med,2022,150:106018.
  55. 55.
    JOSHI M,MELO D P,OUYANG D,et al.Current and future applications of artificial intelligence in cardiac CT[J].Curr Cardiol Rep,2023,25(3):109-117.
  56. 56.
    PAN C L,LIU L C,PAN D.Integration of CNN and Transformer for 3D coronary artery CT image segmentation[J].Electron Meas Technol,2025,48(6):143-151.
  57. 57.
    CAO Y H,LI C,YANG J J,et al.Application status of AI in diagnosis and treatment of cardiovascular diseases[J].Chin Bull Life Sci,2022,34(8):918-928.
  58. 58.
    AL'AREF S J,MALIAKAL G,SINGH G,et al.Machine learning of clinical variables and coronary artery calcium scoring for the prediction of obstructive coronary artery disease on coronary computed tomography angiography:Analysis from the CONFIRM registry[J].Eur Heart J,2020,41(3):359-367.
  59. 59.
    KOLOSSVÁRY M,PARK J,BANG J I,et al.Identification of invasive and radionuclide imaging markers of coronary plaque vulnerability using radiomic analysis of coronary computed tomography angiography[J].Eur Heart J Cardiovasc Imaging,2019,20(11):1250-1258.
  60. 60.
    YANG S,KOO B K,HOSHINO M,et al.CT angiographic and plaque predictors of functionally significant coronary disease and outcome using machine learning[J].JACC Cardiovasc Imag,2021,14(3):629-641.
  61. 61.
    SHI Z,ZHU C C,DEGNAN A J,et al.Identification of high-risk plaque features in intracranial atherosclerosis:Initial experience using a radiomic approach[J].Eur Radiol,2018,28(9):3912-3921.
  62. 62.
    SU J,ZHANG Y,KE Q Q,et al.Mobilizing artificial intelligence to cardiac telerehabilitation[J].Rev Cardiovasc Med,2022,23(2):45.
  63. 63.
    CAPPON G,VETTORETTI M,SPARACINO G,et al.Continuous glucose monitoring sensors for diabetes management:A review of technologies and applications[J].Diabetes Metab J,2019,43(4):383-397.
  64. 64.
    BEQUETTE B W.Continuous glucose monitoring:Real-time algorithms for calibration,filtering,and alarms[J].J Diabetes Sci Technol,2010,4(2):404-418.
  65. 65.
    VETTORETTI M,CAPPON G,FACCHINETTI A,et al.Advanced diabetes management using artificial intelligence and continuous glucose monitoring sensors[J].Sensors (Basel),2020,20(14):3870.
  66. 66.
    GEHI A K,ALI S,NA B,et al.Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease:The heart and soul study [J].Arch Intern Med,2007,167(16):1798-1803.
  67. 67.
    MARTANI A,GENEVIÈVE L D,POPPE C,et al.Digital pills:A scoping review of the empirical literature and analysis of the ethical aspects [J].BMC Med Ethics,2020,21(1):3.
  68. 68.
    CHEN T Y,ZHANG X L,JIANG H T,et al.Are you smoking? Automatic alert system helping people keep away from cigarettes[J].Smart Health,2018,9-10:158-169.
  69. 69.
    LI S,ZHANG L D,CHENG Y Y,et al.Discussion on rhythmical changes and treatment of blood pressure of hypertension from TCM time medicine[J].China J Tradit Chin Med Pharm,2020,35(6):3011-3014.
  70. 70.
    HUI X S.Mechanism of Panax notoginseng regulating miR-370-3p/IRAK2/NF-κB pathway to improve vascular endothelial function injury in hyperlipidemia[D].Beijing:China Academy of Chinese Medical Sciences,2022.
  71. 71.
    WANG J Y.The mechanism of Xueguan Kangshuai Formula via the regulation of miR-146a/TRAF6/NF-κB to improve vascular aging[D].Beijing:China Academy of Chinese Medical Sciences,2021.
  72. 72.
    CHEN H W,LI J,LIN F,et al.Effect of Xuanbi Antong formula in improving ventricular remodeling in myocardial infarction rats and its mechanism[J].Chin J Exp Tradit Med Form,2017,23(23):71-78.
  73. 73.
    WANG J,YAO K W,XING Y W,et al.Clinical research and practice on the combination of coronary heart disease symptoms and conditions[J].J Tradit Chin Med,2015,56(24):2089-2092,2097.
  74. 74.
    WANG J,YAO K W,LI J,et al.Researches on the theoretical innovation and clinical application of "phlegm-blood stasis-stagnation-deficiency" in coronary heart disease[J].Chin J Integr Med,2019,39(8):1015-1019.
  75. 75.
    WANG J,LI J S,YAO K W,et al.Research on quantified diagnosis and combining diseases with syndrome of blood stasis[J].J Chin Integr Med,2003,1(1):21-24.
  76. 76.
    LI H Z,WANG J,HE H Q,et al.Construction of diagnosis-treatment knowledge model of diseases and syndrome combination for coronary heart disease angina pectoris:Based on traditional Chinese medicine thinking[J].J Tradit Chin Med,2019,60(15):1288-1293.
  77. 77.
    HAN X X,ZHU H X,TANG Z S,et al.Research status and prospects of artificial intelligence in clinical application of traditional Chinese medicine[J].Chin J Tradit Chin Med Pharm,2025,40(4):1527-1531.
  78. 78.
    LI H Z,WANG J,GUO Y C,et al.Research on diagnosis and prescription system of coronary heart disease with syndrome elements based on improved Transformer algorithm[J].Chin J Exp Tradit Med Form,2023,29(1):148-154.
  79. 79.
    YANG B Y,YE X M,XIA S T,et al.Study on the development of dual referral system and the hierarchical medical system[J].Chin Health Stand Manage,2018,9(23):22-25.
  80. 80.
    CHEN J,HE X W,YAN Z J,et al.Study on influencing factors of doctors' two-way referral behavior in urban medical association:A case study of a hospital medical association in Beijing[J].Chin J Soc Med,2022,39(6):693-698.
  81. 81.
    LI J L,JIANG S H,CHEN W,et al.Discussion on the construction of emergency passageway and two-way referral platform[J].Chin Commun Doct,2024,40(22):148-150.

続きを読む

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website